istar medical 2017 · • current and past board memberships include adocia, confo therapeutics,...
Post on 11-Sep-2018
214 Views
Preview:
TRANSCRIPT
Executive Summary
• Clinical stage medical technology company
• Targeting Glaucoma, a major market with high
potential for growth
• Innovative biocompatible STAR® material
offers unique potential for treating glaucoma
through bio-integration
• MINIject™ designed to be best in class MIGS
device
• Strong, experienced management team, board
of Directors and Scientific Advisors
2
STAR® material
MINIject™
History of iSTAR Medical
3
2011STARflo Glaucoma
Drainage Device;
First In Human
2013Series A financing
€4 Mln
2014First multicentre
clinical trial for
STARflo
2016Series B financing
€10 Mln
2010iStar Medical
founded
2016MINIject (MIGS)
Design finalised
2017MINIject
First In Human
2011Grants from
Belgium Region
Board of Directors and Management Team
Michel Lussier, Chairman of the Board
• 30 years of experience in Medical Technology
• Chairman of Celyad, founder of Medpole, a European distribution incubator for medical
device start-up companies and co-founder of Cardio3 Biosciences
• Formerly a senior executive with Medtronic and Volcano
Philippe Degive
• Representative of Société Régionale d'Investissement de Wallonie (“SRIW”)
• Formerly with BNP Paribas Fortis
• Current and past board memberships include Bone Therapeutics, Promethera Biosciences,
Euroscreen, Cardio Life Research
David Guyer, MD
• CEO of multiple public and private biotechnology companies
• Co-Founder, Chairman and CEO of Ophthotech Corp.
• Previously: SV Life Sciences. Co-founded at Eyetech Pharmaceuticals, Inc.,
• B.S. from Yale College & M.D. from Johns Hopkins
Max Maginness
• President and co-founder, Healionics Corporation
• Formerly with Siemens Medical, ATL (now Philips Ultrasound) and subsidiaries of CIBA-
Geigy managing multiple new product development and technology transfer projects
Marc Nolet de Brauwere
• 30 years of industry experience and a successful track record in building and leading
companies in ophthalmology
• Currently board membership include Bone Therapeutics, Cardiatis, Mymicroinvest, Endo
Tools Therapeutics, Biotech Coaching and Aliaxis
• CEO of PhysIOL,, an innovative med-tech company active in the conception, manufacturing
and sales of cutting-edge intraocular lenses (IOLs)
Katya Smirnyagina
• Partner, Capricorn Health-Tech Venture Fund
• Formerly with Alta Partners
• Current and past board memberships include Adocia, Confo Therapeutics, Nexstim Oy,
Ablynx, Cerenis Therapeutics, Innate Pharma and Kiadis Pharma
Michel Vanbrabant, CEO
• 20 years of experience in Medical Technology
• Held several international positions at leading MedTech companies including
Guidant Inc. (now Boston Scientific) and St.Jude Medical
• Experience in several start-up organisations with a focus on go-to market strategy
and implementation
Zubair Hussain, Regulatory & Clinical Affairs
• 20+ years experience in Regulatory, Quality, Compliance and Clinical Affairs for
Pharmaceutical and Medical Device companies.
• Formerly with Pfizer, Alcon, Ipsen
• Experience in Global Regulatory, both strategic and operational, Clinical Affairs,
including in Vision care
Dan Scherrer, Operations
• 20+ years experience in Operations and Supply Chain Management for Medical
Device, Food and Electronics.
• Formerly with DePuy Spine (JNJ), Synthes, Biwi
• Experience in overall operations from Product Development to Supply Chain
Pierre Geens, R&D
• 15 years of experience in manufacturing, engineering, and international quality
assurance roles
• Formerly with GSK Pharmaceuticals, Baxter Healthcare, GSK Vaccines
• Experience in manufacturing, validation, R&D quality system, quality assurance and
market access
Cecile Roy, Manufacturing
• 5 years of research experience with bio-polymeric products for drug delivery
applications
• Co-inventor of the MINIject device
• Master’s Degree in Civil Engineering and a Ph.D. in Engineering Sciences from the
Université Catholique de Louvain
4
Bo
ard
of
Dir
ect
ors
Man
ag
em
en
t T
eam
Marty Wax, MD
• Chief Medical Officer and Executive VP of R&D at PanOptica, Inc.
• Formerly Vice-President and Head of Discovery Research and Pre-Clinical
Sciences at Alcon Laboratories
• Clinical Professor of Ophthalmology and Visual Sciences at Rutgers Medical
School in Newark, N.J.
Bo
ard
Glaucoma: Progressive, sight-threatening disease
5
Sources:
1. Market Scope estimates for Glaucoma prevalence (September 2016)
2. WHO/NMH/PBD/12.01 – Global data on visual impairments 2010 & Glaucoma Devices: Progress On Multiple Fronts, Elsevier Business Intelligence, April 2013
>80
million
people
>90 million
people 1
2016 2021
Blocked drainage
canal builds up
fluid
Excess fluid increases
pressure which
damages optic nerve
Second cause of blindness after macular degeneration worldwide 22
Therapeutic options aim at lowering intraocular pressure (IOP)
iSTAR Product Pipeline
6
Feasibility study
complete
Multi-center Study in
progress
Product Development
complete
First in Human H1-2017
STARflo MINIject
STAR BiomaterialProof of Concept
(Ab Externo Version)
MIGS
(Ab Interno Version)
The STAR® anti-fibrotic material
7
Medical grade silicone with precision-pore geometry
Soft, flexible, tissue-friendly
STAR® material developed at the University of Washington, Seattle, USA
Pore Throat
Rabbit Study:
Suprachoroidal Placement – 6m Follow Up
8
IrisCornea
Sclera
Choroid
STARflo
Retina
No Encapsulation
observed as shown by the
absence of a continuous
surrounding fibrous
capsule, nor continuous
macrophage, nor a
continuous fibroblast layer
Exceptional
Biointegration
of the device with
surrounding tissue
colonizing the porous
structure while preserving
in vivo drainage efficacy
Source:
Prof. Nathalie Collignon (CHU of Liège, Liège, Belgium); In-
vivo: CER Groupe (Marloie, Belgium); Histology: GIGA-ULg
Immunohistology Platform (University of Liège, Liège,
Belgium). March 2013.
The STARflo Drainage Implant
9
STARflo
Inserted through an
incisional surgical
procedure by
Glaucoma surgeons
Intended Benefits
STARflo: A Unique Drainage Implant for Glaucoma
10
Medical-grade silicone with micro-porous geometry
Soft, flexible, biocompatible
STAR Material
Bleb-free surgery
Acts on the natural uveoscleral
drainage pathway
Anti-fibrotic biomaterial
Adjunct of antimetabolites
(mitomycin) not required
Living tissue integration
without blockage
Sustained efficacy
Fewer complications
Less post-op patient
management
Better drainage
Low scarring
and infection
Supra-choroidal Placement
STARflo
The MINIject Glaucoma Drainage System
11
• Designed to be a high-performing, safe MIGS device resulting in significant and
sustained intraocular pressure (IOP) reduction
• Developed in close collaboration with world leading scientific and clinical advisors –
understanding real patient needs
• Ergonomic shape for optimal
grip and precision
Handle
Shaft
• Pre-loaded with implant
• Smooth pull-back release
mechanism
MINIject
MINIject Delivery
12
Targeting suprachoroidal space
Avoiding bleb formation
Minimising post-operative patient management
• Delivery through a small corneal incision of 2.2 mm
• Can be performed by cataract and glaucoma surgeons
top related